Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Barto J. Otten is active.

Publication


Featured researches published by Barto J. Otten.


Archives of Disease in Childhood | 1996

Final height in central precocious puberty after long term treatment with a slow release GnRH agonist

Wilma Oostdijk; B. Rikken; S. Schreuder; Barto J. Otten; Roelof J. Odink; C.W. Rouwé; M. Jansen; W.J. Gerver; J.J.J. Waelkens; S.L. Drop

OBJECTIVE: To study the resumption of puberty and the final height achieved in children with central precocious puberty (CPP) treated with the GnRH agonist triptorelin. PATIENTS: 31 girls and five boys with CPP who were treated with triptorelin 3.75 mg intramuscularly every four weeks. Girls were treated for a mean (SD) of 3.4 (1.0) years and were followed up for 4.0 (1.2) years after the treatment was stopped. RESULTS: The rate of bone maturation decreased during treatment and the predicted adult height increased from 158.2 (7.4) cm to 163.9 (7.5) cm at the end of treatment (p < 0.001). When treatment was stopped bone maturation accelerated, resulting in a final height of 161.6 (7.0) cm, which was higher than the predicted adult height at the start of treatment (p < 0.001). Height at the start of treatment was the most important factor positively influencing final height (r = 0.75, p < 0.001). Bone age at cessation of treatment negatively influenced final height (r = -0.52, p = 0.03). A negative correlation between bone age and height increment after discontinuation of treatment was observed (r = -0.85, p = 0.001). Residual growth capacity was optimal when bone age on cessation of treatment was 12 to 12.5 years. Body mass index increased during treatment and remained high on cessation. At final height, the ratio of sitting height to subischial leg length was normal. Menarche occurred at 12.3 (1.1) years, and at a median (range) of 1.1 (0.4 to 2.6) years after treatment was stopped. The ovaries were normal on pelvic ultrasonography. CONCLUSIONS: Treatment of CPP with triptorelin increases final height, with normal body proportions, and seems to increase body mass index. The best results were achieved in girls who were taller at the start of treatment. Puberty was resumed after treatment, without the occurrence of polycystic ovaries.


Best Practice & Research Clinical Endocrinology & Metabolism | 2009

Testicular adrenal rest tumours in congenital adrenal hyperplasia

H.L. Claahsen-van der Grinten; Barto J. Otten; M.M.L. Stikkelbroeck; Fred C.G.J. Sweep; A.R.M.M. Hermus

In adult patients with congenital adrenal hyperplasia (CAH) the presence of testicular adrenal rest tumours (TART) is an important cause of gonadal dysfunction and infertility. In the last decade several papers have focused on the origin and pathogenesis of these tumours. In this paper we review the embryological, histological, biochemical and clinical features of TART and discuss the treatment options. Furthermore, we propose a new five-stage classification of TART, based on sonographic, clinical and biochemical parameters, that may lead to a better follow up and treatment of patients with TART.


European Journal of Endocrinology | 2007

Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Hedi L. Claahsen-van der Grinten; Fred C.G.J. Sweep; Johan G. Blickman; A.R.M.M. Hermus; Barto J. Otten

OBJECTIVE Testicular adrenal rest tumours (TART) are a well-known complication in adult male patients with congenital adrenal hyperplasia (CAH), with a reported prevalence of up to 94%. In adulthood, the tumours are associated with gonadal dysfunction most probably due to longstanding obstruction of the seminiferous tubules. The aim of our study was to determine the presence of TART and their influence on gonadal function in childhood. DESIGN Retrospective study. PATIENTS AND METHODS Scrotal ultrasound was performed in 34 children with CAH due to 21-hydroxylase deficiency who were between 2 and 18 years old. FSH, LH, testosterone and inhibin B concentrations were measured in serum of 27 patients. RESULTS TART were detected by ultrasound in 8 out of 34 (24%) children. In two of them, bilateral tumours were found. All lesions were located in the rete testis. Seven patients had the salt-wasting type of CAH; one patient had the simple virilising type of CAH. Mean tumour size was 4.1 mm (range 2-8 mm). In none of the patients were the tumours palpable. Two children with TART were between 5 and 10 years old, the other six children were above 10 years old. In all children with TART, LH, FSH, testosterone and inhibin B levels were similar to the patients without TART. CONCLUSION TART can be found in CAH children before the age of 10 years. The absence of gonadal dysfunction in our group of children suggests that gonadal dysfunction as frequently reported in adult CAH patients with TART develops after childhood.


European Journal of Pediatrics | 2005

Brain-Thyroid-Lung syndrome: A patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene

M.A.A.P. Willemsen; Guido J. Breedveld; Siep Wouda; Barto J. Otten; Jan L. Yntema; Martin Lammens; Bert B.A. de Vries

A 23-year-old man was diagnosed with pulmonary alveolar proteinosis at the age of 11 months, and primary hypothyroidism gradually developed during infancy. He had delayed developmental milestones and severe hypotonia that evolved into non-progressive chorea during childhood. He died from large cell lung carcinoma at the age of 23 years. A de novo heterozygous insertion mutation 859–860insC in the TITF-1 gene was demonstrated. Conclusion: TITF-1 gene mutations should be considered in paediatric and adult patients with unexplained (combinations of) chorea, mental retardation, primary hypothyroidism, and chronic lung disease. Introduction of a name for the disorder, e.g. Brain-Thyroid-Lung syndrome, would probably facilitate further recognition. Whether the TITF-1 gene mutation in this patient predisposed to the development of lung cancer remains speculative.


The Journal of Clinical Endocrinology and Metabolism | 2008

High Prevalence of Central Adrenal Insufficiency in Patients with Prader-Willi Syndrome

Roderick F. A. de Lind van Wijngaarden; Barto J. Otten; Dederieke A. M. Festen; Koen F. M. Joosten; Frank H. de Jong; Fred C.G.J. Sweep; Anita Hokken-Koelega

CONTEXT The annual death rate of Prader-Willi syndrome (PWS) patients is very high (3%). Many of these deaths are sudden and unexplained. OBJECTIVE Because most deaths occur during moderate infections and PWS patients suffer from various hypothalamic insufficiencies, we investigated whether PWS patients suffer from central adrenal insufficiency (CAI) during stressful conditions. DESIGN Overnight single-dose metyrapone tests were performed. Metyrapone (30 mg/kg) was administered at 2330 h. At 0400, 0600, and 0730 h, ACTH, 11-deoxycortisol, cortisol, and glucose levels were measured. Diurnal salivary cortisol profiles were assessed on a different day at wake-up, 30 min after wake-up, at 1400 h, and at 2000 h. SETTING The study was conducted in a pediatric intensive care unit. PATIENTS Patients included 25 randomly selected PWS patients. MAIN OUTCOME MEASURE Patients were considered as having CAI when ACTH levels remained below 33 pmol/liter at 0730 h. RESULTS Median (interquartile range) age was 9.7 (6.8-13.6) yr. Fifteen patients (60%) had an insufficient ACTH response (CAI, P < 0.001). There was no significant difference in age, gender, genotype, and body mass index SD score between patients with CAI and those without. Morning salivary cortisol levels and diurnal profiles were normal in all children, suggesting that CAI becomes apparent only during stressful conditions. CONCLUSIONS Strikingly, 60% of our PWS patients had CAI. The high percentage of CAI in PWS patients might explain the high rate of sudden death in these patients, particularly during infection-related stress. Based on our data, one should consider treatment with hydrocortisone during acute illness in PWS patients unless CAI has recently been ruled out with a metyrapone test.


Clinical Endocrinology | 2008

Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome

Dederieke A. M. Festen; M. Wevers; Ann Christin Lindgren; B. Böhm; Barto J. Otten; Jan Wit; Hugo J. Duivenvoorden; Anita Hokken-Koelega

Background  Prader–Willi syndrome (PWS) is a neurogenetic disorder characterized by muscular hypotonia, psychomotor delay, feeding difficulties and failure to thrive in infancy. GH treatment improves growth velocity and body composition. Research on the effects of GH on psychomotor development in infants with PWS is limited.


Obstetrical & Gynecological Survey | 2003

Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Nike M. M. L. Stikkelbroeck; A.R.M.M. Hermus; Didi D.M. Braat; Barto J. Otten

Fertility in women with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency appears to be reduced. The purpose of this review is to summarize the reported evidence about subfertility in women with CAH and to review the causes of reduced fertility. Compared with a non-CAH female population, pregnancy and live-birth rates are severely reduced in salt-wasting patients, mildly reduced in simple virilizing patients, and normal in nonclassical patients. Several factors have been suggested to contribute to the impaired fertility in CAH females: adrenal overproduction of androgens and progestins (17-hydroxyprogesterone and progesterone), ovarian hyperandrogenism, polycystic ovary syndrome, ovarian adrenal rest tumors, neuroendocrine factors, genital surgery, and psychological factors such as delayed psychosexual development, reduced sexual activity and low maternal feelings. It is obvious that these factors are interrelated. Improving endocrine, surgical, and psychological management could contribute to improving fertility chances in these patients. Target Audience: Obstetricians & Gynecologists, Family Physicians Learning Objectives: After completion of this article, the reader will be able to define the various types of CAH, to describe the fertility issues in the CAH patients, to outline the various other causes of hyperandrogenism, and to list the treatment options for the patient with CAH.


Clinical Endocrinology | 2008

Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.

Dederieke A. M. Festen; Roderick F. A. de Lind van Wijngaarden; Marielle Van Eekelen; Barto J. Otten; Jan M. Wit; Hugo J. Duivenvoorden; Anita Hokken-Koelega

Background  Prader–Willi syndrome (PWS) children have impaired growth, and abnormal body composition. Previous 1‐year controlled studies showed improvement of height and body composition during GH‐treatment.


The Journal of Clinical Endocrinology and Metabolism | 2012

Beneficial Effects of Growth Hormone Treatment on Cognition in Children with Prader-Willi Syndrome: A Randomized Controlled Trial and Longitudinal Study

Elbrich P. C. Siemensma; Roderick F. A. Tummers-de Lind van Wijngaarden; Dederieke A. M. Festen; Zyrhea C. E. Troeman; A. A. E. M. (Janielle) van Alfen-van der Velden; Barto J. Otten; Joost Rotteveel; Roelof J. Odink; G. C. B. Bindels-de Heus; Mariette van Leeuwen; Danny A. J. P. Haring; W. Oostdijk; Gianni Bocca; E. C. A. Mieke Houdijk; A. S. Paul van Trotsenburg; J. J. Gera Hoorweg-Nijman; Hester van Wieringen; René C. F. M. Vreuls; Petr Jira; Eelco J. Schroor; Evelyn van Pinxteren-Nagler; Jan Willem Pilon; L. Lunshof; Anita Hokken-Koelega

BACKGROUND Knowledge about the effects of GH treatment on cognitive functioning in children with Prader-Willi syndrome (PWS) is limited. METHODS Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment. Cognitive functioning was measured biennially by short forms of the WPPSI-R or WISC-R, depending on age. Total IQ (TIQ) score was estimated based on two subtest scores. RESULTS During the randomized controlled trial, mean sd scores of all subtests and mean TIQ score remained similar compared to baseline in GH-treated children with PWS, whereas in untreated controls mean subtest sd scores and mean TIQ score decreased and became lower compared to baseline. This decline was significant for the Similarities (P = 0.04) and Vocabulary (P = 0.03) subtests. After 4 yr of GH treatment, mean sd scores on the Similarities and Block design subtests were significantly higher than at baseline (P = 0.01 and P = 0.03, respectively), and scores on Vocabulary and TIQ remained similar compared to baseline. At baseline, children with a maternal uniparental disomy had a significantly lower score on the Block design subtest (P = 0.01) but a larger increment on this subtest during 4 yr of GH treatment than children with a deletion. Lower baseline scores correlated significantly with higher increases in Similarities (P = 0.04) and Block design (P < 0.0001) sd scores. CONCLUSIONS Our study shows that GH treatment prevents deterioration of certain cognitive skills in children with PWS on the short term and significantly improves abstract reasoning and visuospatial skills during 4 yr of GH treatment. Furthermore, children with a greater deficit had more benefit from GH treatment.


Clinical Endocrinology | 1995

Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues

J.M. Wit; Bart Boersma; S.M.P.F. de Muinck Keizer-Schrama; H. E. Nienhuis; W. Oostdijk; Barto J. Otten; H.A. Delemarre-van de Waal; Maarten Reeser; J.J.J. Waelkens; B. Rikken; Guy Massa

BACKGROUND AND OBJECTIVE Growth hormone treatment In children with Idiopathic short stature (ISS) leads to growth acceleration in the first years, but the effect on final height is still poorly documented. We therefore studied the long‐term effect of GH therapy in children with Idiopathic short stature.

Collaboration


Dive into the Barto J. Otten's collaboration.

Top Co-Authors

Avatar

A.R.M.M. Hermus

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

J.M. Wit

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Anita Hokken-Koelega

Erasmus University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jan M. Wit

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Theo C. J. Sas

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fred C.G.J. Sweep

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

Hedi L. Claahsen-van der Grinten

Radboud University Nijmegen Medical Centre

View shared research outputs
Top Co-Authors

Avatar

Leonie A. Menke

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Nike M. M. L. Stikkelbroeck

Radboud University Nijmegen Medical Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge